Page 1 of 53
IgNS Ig Certified Pharmacist (IgCP) Credential Exam
QUESTIONS AND VERIFIED ANSWERS WITH
RATIONALES JUST RELEASED
IgNS Ig Certified Pharmacist (IgCP) Credential Practice Exam — Summarized Coverage
The Ig Certified Pharmacist (IgCP) exam, administered by the Immunoglobulin National Society (IgNS),
evaluates pharmacist competency in immunoglobulin (Ig) therapy management, including IVIG and
SCIG use, patient selection, dosing, monitoring, safety, and regulatory standards in specialty infusion
practice.
1. Immunology & Ig Therapy Fundamentals
• Structure and function of immunoglobulins (IgG, IgA, IgM, IgE, IgD)
• Passive immunity vs active immunity concepts
• Mechanism of immunoglobulin replacement therapy
• Immune system modulation by IVIG (anti-inflammatory and immunomodulatory effects)
• Complement system interaction with Ig products
2. Immunoglobulin Products (IVIG & SCIG)
• IVIG vs SCIG differences (route, absorption, pharmacokinetics)
• Plasma-derived product manufacturing (pooled donor plasma)
• Product formulations and concentration differences
• Subcutaneous absorption via lymphatic system
• Bioavailability and steady-state serum Ig levels
• Switching between IVIG and SCIG therapies
3. Clinical Indications for Ig Therapy
• Primary immunodeficiency disorders (PID)
• Secondary immunodeficiencies (HIV, hematologic malignancies)
• Autoimmune and inflammatory conditions (e.g., ITP, CIDP, Kawasaki disease)
• Neurologic indications (GBS, myasthenia gravis, multifocal motor neuropathy)
• Off-label use principles and evidence-based selection
4. Patient Assessment & Selection
• Baseline immune function testing (IgG levels, antibody titers)
• Eligibility criteria for Ig therapy initiation
• Risk stratification (thromboembolic risk, renal impairment, IgA deficiency)
• Contraindications and precautions
• Individualized dosing considerations (weight-based, clinical response-based)
5. Dosing, Administration & Infusion Protocols
• IVIG loading vs maintenance dosing strategies
• SCIG weekly or biweekly dosing regimens
• Infusion rate escalation protocols
• Dose adjustments based on trough IgG levels
• Pre-medication strategies (antihistamines, acetaminophen, steroids)
• Infusion site selection and rotation for SCIG
, Page 2 of 53
6. Pharmacokinetics & Pharmacodynamics
• Distribution of Ig products in intravascular vs extravascular compartments
• Half-life of IgG and steady-state kinetics
• Absorption differences: IV bolus vs SC lymphatic uptake
• Mechanisms of action in immune modulation (Fc receptor blockade, cytokine inhibition)
7. Adverse Effects & Safety Monitoring
• Infusion reactions (headache, fever, chills, hypotension)
• Thromboembolic complications
• Renal toxicity (especially sucrose-containing IVIG)
• Aseptic meningitis risk
• Hemolysis due to blood group antibodies in IVIG
• SCIG local site reactions
• Monitoring labs and clinical follow-up
8. Drug Interactions & Clinical Considerations
• Interference with live vaccines (delayed vaccine response)
• Interaction with monoclonal antibodies and biologics
• Effect on serologic testing and lab results
• Timing of vaccination after Ig therapy
9. Regulatory, Storage & Handling
• FDA-regulated biologic product requirements
• Cold chain storage and handling requirements
• Expiration, lot tracking, and recall procedures
• Documentation and infusion center compliance standards
10. Complications & Emergency Management
• Anaphylaxis recognition and treatment
• Managing severe infusion reactions
• Fluid overload risk in cardiac/renal patients
• Acute renal failure management protocols
• Thrombosis risk mitigation strategies
11. Patient Monitoring & Outcomes
• IgG trough level monitoring
• Infection rate reduction tracking
• Quality of life and symptom improvement assessment
• Long-term therapy evaluation and discontinuation criteria
12. Ethics, Legal & Professional Practice
• Informed consent for blood-derived products
• Patient autonomy and shared decision-making
• Allocation of high-cost therapies
• Documentation and liability in infusion practice
• Interprofessional collaboration (physicians, pharmacists, nurses)
, Page 3 of 53
13. Practice-Based Scenario Questions (Exam Style Core)
• Choosing IVIG vs SCIG for a specific patient profile
• Managing infusion reaction during therapy
• Adjusting dosing for renal impairment or obesity
• Identifying inappropriate Ig therapy use
• Interpreting IgG trough levels and clinical response
• Selecting correct premedication strategy
• Handling vaccine scheduling conflicts
IgNS Ig Certified Pharmacist (IgCP) Practice Exam — Batch 1 (1–50)
1.
Which immunoglobulin is the most abundant in human serum and commonly used in IVIG therapy?
A. IgA
B. IgE
C. IgG
D. IgM
Answer: C
Rationale: IgG is the predominant serum antibody and the main component of IVIG products.
2.
What is the primary mechanism of immunoglobulin replacement therapy in primary immunodeficiency?
A. Stimulate T-cell destruction
B. Replace missing or deficient IgG antibodies
C. Increase complement activation only
D. Suppress bone marrow function
Answer: B
Rationale: IVIG/SCIG provides passive replacement of missing antibodies.
3.
Which route of administration is characteristic of SCIG therapy?
A. Intravenous infusion only
B. Subcutaneous infusion into fatty tissue
C. Intramuscular injection
D. Oral administration
Answer: B
Rationale: SCIG is delivered into subcutaneous tissue for gradual absorption.
, Page 4 of 53
4.
What is a key pharmacokinetic difference between IVIG and SCIG?
A. SCIG produces rapid peak serum levels
B. IVIG produces steady-state low serum levels
C. SCIG produces more stable serum IgG levels over time
D. IVIG has no systemic absorption
Answer: C
Rationale: SCIG leads to more stable IgG levels due to frequent dosing.
5.
Which condition is a primary indication for immunoglobulin replacement therapy?
A. Hypertension
B. Primary immunodeficiency disorders
C. Type 2 diabetes
D. Asthma only
Answer: B
Rationale: PID patients lack sufficient antibody production.
6.
Which immunoglobulin product is derived from pooled human plasma donations?
A. Monoclonal antibody only
B. Recombinant insulin
C. IVIG and SCIG products
D. Synthetic steroids
Answer: C
Rationale: Ig products are plasma-derived biologics.
7.
What is the primary role of IVIG in autoimmune disease treatment?
A. Increase bacterial growth
B. Modulate immune response and reduce inflammation
C. Destroy red blood cells
D. Increase antibody destruction
Answer: B
Rationale: IVIG has immunomodulatory and anti-inflammatory effects.
IgNS Ig Certified Pharmacist (IgCP) Credential Exam
QUESTIONS AND VERIFIED ANSWERS WITH
RATIONALES JUST RELEASED
IgNS Ig Certified Pharmacist (IgCP) Credential Practice Exam — Summarized Coverage
The Ig Certified Pharmacist (IgCP) exam, administered by the Immunoglobulin National Society (IgNS),
evaluates pharmacist competency in immunoglobulin (Ig) therapy management, including IVIG and
SCIG use, patient selection, dosing, monitoring, safety, and regulatory standards in specialty infusion
practice.
1. Immunology & Ig Therapy Fundamentals
• Structure and function of immunoglobulins (IgG, IgA, IgM, IgE, IgD)
• Passive immunity vs active immunity concepts
• Mechanism of immunoglobulin replacement therapy
• Immune system modulation by IVIG (anti-inflammatory and immunomodulatory effects)
• Complement system interaction with Ig products
2. Immunoglobulin Products (IVIG & SCIG)
• IVIG vs SCIG differences (route, absorption, pharmacokinetics)
• Plasma-derived product manufacturing (pooled donor plasma)
• Product formulations and concentration differences
• Subcutaneous absorption via lymphatic system
• Bioavailability and steady-state serum Ig levels
• Switching between IVIG and SCIG therapies
3. Clinical Indications for Ig Therapy
• Primary immunodeficiency disorders (PID)
• Secondary immunodeficiencies (HIV, hematologic malignancies)
• Autoimmune and inflammatory conditions (e.g., ITP, CIDP, Kawasaki disease)
• Neurologic indications (GBS, myasthenia gravis, multifocal motor neuropathy)
• Off-label use principles and evidence-based selection
4. Patient Assessment & Selection
• Baseline immune function testing (IgG levels, antibody titers)
• Eligibility criteria for Ig therapy initiation
• Risk stratification (thromboembolic risk, renal impairment, IgA deficiency)
• Contraindications and precautions
• Individualized dosing considerations (weight-based, clinical response-based)
5. Dosing, Administration & Infusion Protocols
• IVIG loading vs maintenance dosing strategies
• SCIG weekly or biweekly dosing regimens
• Infusion rate escalation protocols
• Dose adjustments based on trough IgG levels
• Pre-medication strategies (antihistamines, acetaminophen, steroids)
• Infusion site selection and rotation for SCIG
, Page 2 of 53
6. Pharmacokinetics & Pharmacodynamics
• Distribution of Ig products in intravascular vs extravascular compartments
• Half-life of IgG and steady-state kinetics
• Absorption differences: IV bolus vs SC lymphatic uptake
• Mechanisms of action in immune modulation (Fc receptor blockade, cytokine inhibition)
7. Adverse Effects & Safety Monitoring
• Infusion reactions (headache, fever, chills, hypotension)
• Thromboembolic complications
• Renal toxicity (especially sucrose-containing IVIG)
• Aseptic meningitis risk
• Hemolysis due to blood group antibodies in IVIG
• SCIG local site reactions
• Monitoring labs and clinical follow-up
8. Drug Interactions & Clinical Considerations
• Interference with live vaccines (delayed vaccine response)
• Interaction with monoclonal antibodies and biologics
• Effect on serologic testing and lab results
• Timing of vaccination after Ig therapy
9. Regulatory, Storage & Handling
• FDA-regulated biologic product requirements
• Cold chain storage and handling requirements
• Expiration, lot tracking, and recall procedures
• Documentation and infusion center compliance standards
10. Complications & Emergency Management
• Anaphylaxis recognition and treatment
• Managing severe infusion reactions
• Fluid overload risk in cardiac/renal patients
• Acute renal failure management protocols
• Thrombosis risk mitigation strategies
11. Patient Monitoring & Outcomes
• IgG trough level monitoring
• Infection rate reduction tracking
• Quality of life and symptom improvement assessment
• Long-term therapy evaluation and discontinuation criteria
12. Ethics, Legal & Professional Practice
• Informed consent for blood-derived products
• Patient autonomy and shared decision-making
• Allocation of high-cost therapies
• Documentation and liability in infusion practice
• Interprofessional collaboration (physicians, pharmacists, nurses)
, Page 3 of 53
13. Practice-Based Scenario Questions (Exam Style Core)
• Choosing IVIG vs SCIG for a specific patient profile
• Managing infusion reaction during therapy
• Adjusting dosing for renal impairment or obesity
• Identifying inappropriate Ig therapy use
• Interpreting IgG trough levels and clinical response
• Selecting correct premedication strategy
• Handling vaccine scheduling conflicts
IgNS Ig Certified Pharmacist (IgCP) Practice Exam — Batch 1 (1–50)
1.
Which immunoglobulin is the most abundant in human serum and commonly used in IVIG therapy?
A. IgA
B. IgE
C. IgG
D. IgM
Answer: C
Rationale: IgG is the predominant serum antibody and the main component of IVIG products.
2.
What is the primary mechanism of immunoglobulin replacement therapy in primary immunodeficiency?
A. Stimulate T-cell destruction
B. Replace missing or deficient IgG antibodies
C. Increase complement activation only
D. Suppress bone marrow function
Answer: B
Rationale: IVIG/SCIG provides passive replacement of missing antibodies.
3.
Which route of administration is characteristic of SCIG therapy?
A. Intravenous infusion only
B. Subcutaneous infusion into fatty tissue
C. Intramuscular injection
D. Oral administration
Answer: B
Rationale: SCIG is delivered into subcutaneous tissue for gradual absorption.
, Page 4 of 53
4.
What is a key pharmacokinetic difference between IVIG and SCIG?
A. SCIG produces rapid peak serum levels
B. IVIG produces steady-state low serum levels
C. SCIG produces more stable serum IgG levels over time
D. IVIG has no systemic absorption
Answer: C
Rationale: SCIG leads to more stable IgG levels due to frequent dosing.
5.
Which condition is a primary indication for immunoglobulin replacement therapy?
A. Hypertension
B. Primary immunodeficiency disorders
C. Type 2 diabetes
D. Asthma only
Answer: B
Rationale: PID patients lack sufficient antibody production.
6.
Which immunoglobulin product is derived from pooled human plasma donations?
A. Monoclonal antibody only
B. Recombinant insulin
C. IVIG and SCIG products
D. Synthetic steroids
Answer: C
Rationale: Ig products are plasma-derived biologics.
7.
What is the primary role of IVIG in autoimmune disease treatment?
A. Increase bacterial growth
B. Modulate immune response and reduce inflammation
C. Destroy red blood cells
D. Increase antibody destruction
Answer: B
Rationale: IVIG has immunomodulatory and anti-inflammatory effects.
